Anti-IL6 receptor antibody treatment in patients with COVID-19, is it key to reduce mortality?
Main Article Content
Keywords
SARS Virus, Interleukin-6, COVID 19 Drug Treatment
Abstract
IL-6 receptor antagonists are used for the treatment of several chronic inflammatory diseases. Recently they have been proposed as a treatment for severe COVID‑19 patients. However, there is scarce scientific evidence to support this, which is why it is necessary to generate scientific evidence and perform clinical trials to evaluate the appropriateness of this therapeutic strategy.
References
1. Rose-John S. Interleukin-6 family cytokines. Cold Spring Harb Perspect Biol. 2018;10(2). (Consultado el 14 de abril de 2020.) Disponible en https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5793756/
2. Uciechowski P, Dempke WCM. Interleukin-6:a masterplayer in the cytokine network. Oncology. 2020;98(3):1317.
3. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020 May;55(5):105954. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC711↺/
4. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. chinaXiv. 2020;112. Disponible en:https://www.ser.es/wp-content/uploads/2020/03/TCZ-and-COVID-19.pdf
5. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846-8. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7080116/
6. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may be at least partially responsible for the respiratory failure of COVID-19 patients. J Med Virol. 2020;92(6):552-5. Disponible en:https://pubmed.ncbi.nlm.nih.gov/32104915/
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.